Search

Your search keyword '"Eldad J, Dann"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Eldad J, Dann" Remove constraint Author: "Eldad J, Dann"
155 results on '"Eldad J, Dann"'

Search Results

1. Children on the Gaza-Israel Border: Victims of War

2. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

3. Donor cell leukemia: reappearance of gene mutations in donor cells - more than an incidental phenomenon?

4. Understanding the role of therapeutic plasma exchange in COVID-19

5. The Legacy of Thomas Hodgkin Is Still Relevant 150 Years After His Death. Nothing of Humanity Was Foreign to Him

6. Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians.

9. Limiting surveillance imaging for patients with lymphoma in remission: a mixed methods study leading to a Choosing Wisely recommendation

10. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry

11. Worldwide experience of homozygous familial hypercholesterolaemia:retrospective cohort study

12. Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors

13. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse

14. Hodgkin Disease—An Ever-Evolving Therapy

15. ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY

16. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

17. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

18. The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT

19. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age

20. Donor cell leukemia: reappearance of gene mutations in donor cells - more than an incidental phenomenon?

21. CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma

22. Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease

23. Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received

24. PET-adapted therapy for advanced Hodgkin lymphoma – systematic review

25. A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin’s lymphoma

26. Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

27. In vivo noninvasive microscopy of human leucocytes

28. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations

29. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients

30. Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation

31. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

32. Cognitive impairment in hodgkin lymphoma survivors

34. Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival

35. A 14-Year Experience in the Management of Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura in Northern Israel

36. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee

37. Prevalence of Iron Deficiency and Iron Deficiency Anemia in Strenuously Training Male Army Recruits

38. Measuring blood oxygen saturation along a capillary vessel in human

39. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma

40. Measuring sickle cell morphology in flow using spectrally encoded flow cytometry (Conference Presentation)

41. Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

42. Preoperative Anemia and Blood Transfusion Requirement during Hip Surgery: Synthetic and Real Patient Cohort Data

43. Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

44. Optically Induced Cell Fusion Using Bispecific Nanoparticles

45. Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B

46. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone

47. Transfusion Service and Blood Banking in Natural Disasters

48. Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation

49. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a long-term follow-up

50. PET/CT Adapted Therapy in Hodgkin Disease: Current State of the Art and Future Directions

Catalog

Books, media, physical & digital resources